Literature DB >> 2156646

Mucolysis of the colonic mucus barrier by faecal proteinases: inhibition by interacting polyacrylate.

D A Hutton1, J P Pearson, A Allen, S N Foster.   

Abstract

1. Mucolytic (mucus solubilizing) activity in human faeces has been characterized with both purified human and pig colonic mucin and shown to be mediated by proteolysis. 2. Mucolytic activity was demonstrated by: (i) a drop in mucin viscosity; (ii) a substantial reduction in mucin size, from polymer to degraded subunit, as assessed by Sepharose CL-2B gel filtration; (iii) formation of new N-terminal peptides. 3. Mucolytic activity was also followed in faecal extracts by its proteolytic activity using standard succinyl albumin substrate. Proteolysis extended over the pH range 4.5-11.0. Proteolysis was inhibited at pH 7.5 by soybean trypsin inhibitor and phenylmethanesulphonyl fluoride, suggesting the presence of serine proteinases. 4. The polyacrylate carbomer (934P) inhibited both mucolysis of pig colonic mucin and proteolysis of succinyl albumin. 5. Interaction between the polyacrylate (carbomer 934P) and purified human and pig colonic mucin was demonstrated by a marked synergistic increase in solution viscosity (360% above control). 6. The results demonstrate the presence of a mucolytic activity in the human colonic lumen that has the potential to degrade the mucus barrier, and that polyacrylates inhibit this mucolysis and interact to strengthen the colonic mucus barrier. Polyacrylates may therefore have therapeutic potential in inflammatory bowel disease where luminal proteolytic activity can be raised.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2156646     DOI: 10.1042/cs0780265

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  11 in total

1.  Atomic force microscopy of gastric mucin and chitosan mucoadhesive systems.

Authors:  M P Deacon; S McGurk; C J Roberts; P M Williams; S J Tendler; M C Davies; S S Davis; S E Harding
Journal:  Biochem J       Date:  2000-06-15       Impact factor: 3.857

2.  Pigeon breeders' lung: pigeon intestinal mucin, an antigen distinct from pigeon IgA.

Authors:  A Todd; R M Coan; A Allen
Journal:  Clin Exp Immunol       Date:  1991-09       Impact factor: 4.330

3.  An oral formulation of nicotine for release and absorption in the colon: its development and pharmacokinetics.

Authors:  J T Green; B K Evans; J Rhodes; G A Thomas; C Ranshaw; C Feyerabend; M A Russell
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

4.  Growth in and breakdown of purified rabbit small intestinal mucin by Yersinia enterocolitica.

Authors:  M Mantle; C Rombough
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

5.  Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis.

Authors:  R D Pullan; G A Thomas; M Rhodes; R G Newcombe; G T Williams; A Allen; J Rhodes
Journal:  Gut       Date:  1994-03       Impact factor: 23.059

6.  Helicobacter pylori in vivo causes structural changes in the adherent gastric mucus layer but barrier thickness is not compromised.

Authors:  J L Newton; N Jordan; L Oliver; V Strugala; J Pearson; O F James; A Allen
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

7.  Effect of nicotine on rectal mucus and mucosal eicosanoids.

Authors:  F J Zijlstra; E D Srivastava; M Rhodes; A P van Dijk; F Fogg; H J Samson; M Copeman; M A Russell; C Feyerabend; G T Williams
Journal:  Gut       Date:  1994-02       Impact factor: 23.059

8.  Influence of inflammatory bowel disease on the distribution and concentration of pancreatic secretory trypsin inhibitor within the colon.

Authors:  R J Playford; A M Hanby; K Patel; J Calam
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307

9.  Faecal mucinase activity assessed in inflammatory bowel disease using 14C threonine labelled mucin substrate.

Authors:  A D Dwarakanath; B J Campbell; H H Tsai; D Sunderland; C A Hart; J M Rhodes
Journal:  Gut       Date:  1995-07       Impact factor: 23.059

10.  Protein and Peptide drug delivery: oral approaches.

Authors:  Jessy Shaji; V Patole
Journal:  Indian J Pharm Sci       Date:  2008 May-Jun       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.